Jun. 22 at 1:58 PM
$IFRX https://www.reuters.com/legal/litigation/abbvie-strikes-109-billion-deal-apogee-therapeutics-2026-06-22/
While Apogee and InflaRx pursue different mechanisms of action, both operate in the field of immune-mediated inflammatory and autoimmune diseases. AbbVie's acquisition of Apogee for approximately
$10.9 billion was based on positive Phase 2 clinical data, even before the planned start of Phase 3 trials in the second half of 2026. This demonstrates the value the market can place on successful immunology programs.
It is also noteworthy that Apogee did not have an approved product on the market at the time of the acquisition. Instead, the key factors were the clinical data, market potential, and the strategic value of the program to the acquirer.
For investors in smaller biotechnology companies, this example illustrates that company valuations are not determined solely by current revenues, but often by the quality of clinical data and future commercial potential.
